Industry news that matters to you.  Learn more

Affymetrix Announces Research Collaboration with Massachusetts General Hospital to Validate and Develop New Oncology Biomarker Tests

Affymetrix, Inc. (NASDAQ:AFFX) today announced a research collaboration and licensing agreement with Massachusetts General Hospital (MGH) to co-develop new cancer biomarker tests using the Affymetrix’ QuantiGene® ViewRNA Assay platform*, an in situ hybridization assay capable of single transcript in single-cell detection. As part of this agreement, Affymetrix has the rights to commercialize the new biomarker tests as an outcome of this collaboration.

Early Biomarker for Pancreatic Cancer Identified

Researchers at the University of California, San Diego School of Medicine and Moores Cancer Center have identified a new biomarker and therapeutic target for pancreatic cancer, an often-fatal disease for which there is currently no reliable method for early detection or therapeutic intervention. The paper will be published May 15 in Cancer Research.

Novo Nordisk and Oxford University Team Up to Develop Novel Treatments for Rheumatoid Arthritis and Other Inflammatory Diseases

Today, Novo Nordisk and the Kennedy Institute of Rheumatology at Oxford University jointly announced a new partnership to develop promising new drug candidates and identify novel biomarkers and treatment targets for rheumatoid arthritis and other autoimmune inflammatory diseases.

AQUA Technology Expands to Additional Digital Pathology Platform with Launch of Vectra 2 from Caliper Life Sciences

Caliper Life Sciences, a Perkin-Elmer Company, launched their new Vectra 2 with AQUA technology, an integrated solution for quantification of protein biomarkers in tissue, at the Molecular Targets & Cancer Therapeutics meeting this week. Caliper and HistoRx collaborated on this new immunofluorescent imaging and analysis solution that will deliver objective, quantitative, and reproducible results: an improvement on traditional immunohistochemistry. The new product enables users to leverage the combined imaging and analysis power of Caliper’s Vectra 2, an automated multiplexed and multispectral tissue imaging platform, and AQUA technology, HistoRx’s proprietary image analysis system, to provide an integrated solution to advance the identification and validation of new drug targets and improve assessment of drug response.

ICON PLC and Empire Genomics Partner for the Delivery of Personalised Medicine Services

ICON, a global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries, and Empire Genomics, a leading provider of genomic technologies that enable personalised medicine to be realised, today announced the formation of a strategic alliance.